Trial reportJournal of clinical pharmacology2012
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Trial report in Journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Skeletal muscle mass, strength, and physical performance gains are similar between healthy postmenopausal women and postmenopausal breast cancer survivors after 12 weeks of resistance exercise training.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Lipid profiles within the SABRE trial of anastrozole with and without risedronate.Breast cancer research and treatment · 2012Trial
- Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer.JAMA network open · 2025Article
- Comparative study of dyslipidemia among pre and post - menopausal women.Bioinformation · 2025Article
- Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study.Lipids in health and disease · 2024Article
- Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy.BMC cancer · 2023Article
- Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis.Frontiers in oncology · 2021Review
- Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis.Frontiers in oncology · 2021Article
- Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study.Therapeutic advances in medical oncology · 2020Article
- Article
- Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.Clinical cardiology · 2019Observational
- Comparison of lipid profiles and inflammation in pre- and post-menopausal women with cerebral infarction and the role of atorvastatin in such populations.Lipids in health and disease · 2018Article
- Unilateral Internal Carotid Artery Occlusion After Letrozole Treatment in a Postmenopausal Woman with Breast Cancer.Chinese medical journal · 2016Article
- Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.OncoTargets and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Effects of aromatase inhibitor (AI) therapy on the plasma lipid profile are not clear. Here the authors describe changes in fasting lipids (total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein [LDL], and triglycerides) before and after 3 months of exemestane or letrozole treatment. HDL was reduced in the entire cohort (P < .001) and in the exemestane group (P < .001) but unchanged in the letrozole group (P = .169). LDL was increased in the entire cohort (P = .005) and in the letrozole group (P = .002) but unchanged in the exemestane group (P = .361). This effect was at least partially attributable to washout of tamoxifen as only patients with prior use of tamoxifen experienced a significant increase in LDL. Baseline HDL was an independent predictor of the change in HDL (r(2) = -0.128, P < .001), and prior tamoxifen use was associated with greater increases in LDL (r(2) = 0.057, P < .001). Use of lipid-altering medications did not protect against the exemestane-induced drop in HDL or the increase in LDL observed in women with prior use of tamoxifen taking letrozole. In conclusion, AI treatment and/or washout of tamoxifen induced detrimental changes in the lipid profile of postmenopausal women with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.